PRPO - Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190).

While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician.

Changes in isoform expression may happen over time during the course of treatment. The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.

“This case is a perfect example of why we developed the HemeScreen platform with a panel-based approach to ensure we are providing doctors a more comprehensive picture of their patients’ molecular status”, said Ilan Danieli CEO. “We, and our customers, continue to see the benefits of using the HemeScreen BCR-ABL1 panel both in lab operations efficiencies and results such as these that enable doctors to make more informed care decisions.”

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com .

Please follow us on LinkedIn , Twitter @PrecipioDx and on Facebook .

Inquiries:Contact@precipiodx.com+1-203-787-7888